| Literature DB >> 23426275 |
Ellie Senesael1, Liesbeth Borgermans, Erwin Van De Vijver, Dirk Devroey.
Abstract
INTRODUCTION: There is important evidence on the beneficial effects of treatment of cardiovascular risk factors in terms of morbidity and mortality, but important challenges remain in motivating patients to adhere to their treatment regimen. This study aimed to describe the effectiveness of a quality improvement intervention that included information and regular encouragement by email or letter on cardiovascular risk factors for patients at high risk for cardiovascular disease.Entities:
Keywords: cardiovascular risk; family medicine; lifestyle; tele-health
Mesh:
Year: 2013 PMID: 23426275 PMCID: PMC3576014 DOI: 10.2147/VHRM.S39919
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Baseline patient characteristics, concomitant diseases, and medications
| Advanced care (n = 26) | Usual care (n = 26) | ||
|---|---|---|---|
| Mean age, in years (SD) | 62 (10) | 63 (9) | 0.84 |
| Men, n (%) | 17 (65) | 13 (50) | 0.26 |
| Women, n (%) | 9 (35) | 13 (50) | 0.40 |
| Women aged over 50, n (%) | 9 (100) | 11 (85) | 0.68 |
| TC, in mg/dL (SD) | 202 (38) | 198 (30) | 0.68 |
| HDL-C, in mg/dL (SD) | 60 (26) | 63 (12) | 0.60 |
| TC/HDL-C, in mg/dL (SD) | 4.2 (3.1) | 3.3 (0.9) | 0.16 |
| Myocardial infarction | 0 (0.0) | 1 (3.8) | 1.00 |
| Stroke | 2 (7.7) | 1 (3.8) | 1.00 |
| TIA | 1 (3.8) | 2 (7.7) | 1.00 |
| Vascular disease | 0 (0.0) | 1 (3.8) | 1.00 |
| Diabetes | 2 (7.7) | 4 (15) | 0.66 |
| Angor | 0 (0.0) | 0 (0.0) | 1.00 |
| CABG | 2 (7.7 ) | 1 (3.8) | 1.00 |
| PTCA | 1 (3.7) | 1 (3.8) | 1.00 |
| Aspirin | 7 (27) | 7 (27) | 1.00 |
| Antidiabetic drugs | 2 (7.7) | 4 (15) | 0.66 |
| Lipid-lowering drugs | 12 (46) | 9 (35) | 0.29 |
| Antihypertensive drugs | 15 (58) | 16 (62) | 0.78 |
Note:
Fisher’s exact test was used for subgroups of <10 members.
Abbreviations: CABG, coronary artery bypass graft; HDL-C, high-density lipoprotein cholesterol; PTCA, percutaneous transluminal coronary angioplasty; SD, standard deviation; TC, total cholesterol; TIA, transient ischemic attack.
Patient outcome parameters
| Advanced care (n = 26) | Usual care (n = 26) | ||
|---|---|---|---|
| 0 months | 3 (12) | 4 (15) | 1.00 |
| 3 months | 3 (12) | 4 (15) | 1.00 |
| 6 months | 3 (12) | 4 (15) | 1.00 |
| 0 months | 84.5 (20.4) | 80.8 (15.3) | 0.46 |
| 3 months | 83.9 (20.6) | 80.3 (16.0) | 0.48 |
| 6 months | 83.8 (21.1) | 80.4 (16.1) | 0.52 |
| 0 months | 28.4 (5.7) | 28.1 (4.2) | 0.83 |
| 3 months | 28.2 (5.9) | 28.0 (4.4) | 0.94 |
| 6 months | 28.1 (6.1) | 28.0 (4.5) | 0.97 |
| 0 months | 102.6 (16.3) | 99.6 (14.8) | 0.50 |
| 3 months | 100.8 (16.2) | 99.0 (14.9) | 0.68 |
| 6 months | 99.7 (17.0) | 97.4 (14.5) | 0.59 |
| 0 months | 153 (12) | 153 (13) | 1.00 |
| 3 months | 141 (14) | 142 (15) | 0.87 |
| 6 months | 139 (15) | 139 (14) | 1.00 |
| 0 months | 85 (8) | 88 (10) | 0.24 |
| 3 months | 77 (8) | 81 (10) | 0.12 |
| 6 months | 77 (9) | 80 (9) | 0.24 |
| 0 months | 70 (9) | 70 (6) | 1.00 |
| 3 months | 69 (9) | 66 (7) | 0.19 |
| 6 months | 67 (8) | 69 (11) | 0.46 |
Note:
Fisher’s exact test was used for subgroups of <10 members.
Abbreviation: SD, standard deviation.
Figure 1Evolution of the average systolic blood pressure in both groups at month 0, 3, and 6.
Figure 2Evolution of the average diastolic blood pressure in both groups at month 0, 3, and 6.
Blood pressure, body mass index, and waist circumference target level attainment at month 0, 3, and 6
| Advanced care (n = 26) | Usual care (n = 26) | ||
|---|---|---|---|
| Systolic blood pressure < 140 mmHg (130 mmHg for diabetics), n (%) | |||
| Month 0 | 1 (4) | 0 (0) | 1.00 |
| Month 3 | 9 (35) | 3 (12) | 0.10 |
| Month 6 | 12 (46) | 10 (39) | 0.57 |
| Diastolic blood pressure < 90 mmHg (80 mmHg for diabetics), n (%) | |||
| Month 0 | 12 (46) | 8 (31) | 0.39 |
| Month 3 | 19 (73) | 18 (69) | 0.76 |
| Month 6 | 23 (89) | 18 (69) | 0.09 |
| Blood pressure < 140/90 mmHg (130/80 mmHg for diabetics), n (%) | |||
| Month 0 | 1 (4) | 0 (0) | 1.00 |
| Month 3 | 9 (35) | 2 (8) | 0.05 |
| Month 6 | 12 (46) | 9 (35) | 0.57 |
| Body mass index < 25 m/kg, n (%) | |||
| Month 0 | 6 (23) | 7 (27) | 1.00 |
| Month 3 | 7 (27) | 7 (27) | 0.75 |
| Month 6 | 7 (27) | 9 (35) | 0.76 |
| Body mass index < 30 m/kg, n (%) | |||
| Month 0 | 17 (65) | 16 (62) | 0.77 |
| Month 3 | 17 (65) | 16 (62) | 0.77 |
| Month 6 | 17 (65) | 16 (62) | 0.77 |
| Waist circumference < 102 cm for men or < 88 cm for women, n (%) | |||
| Month 0 | 7 (27) | 9 (35) | 0.76 |
| Month 3 | 10 (39) | 10 (39) | 1.00 |
| Month 6 | 12 (46) | 10 (39) | 0.78 |
Note:
Fisher’s exact test was used for subgroups of <10 members.
Proportion of patients with a low (<5%), moderate (5%–10%) and high (≥10%) cardiovascular risk Systematic COronary Risk Evaluation (SCORE)a at month 0, 3, and 6
| Advanced care (n = 26) | Usual care (n = 26) | ||
|---|---|---|---|
| Low (<5%) | 12 (43) | 10 (39) | 0.57 |
| Moderate (5%–10%) | 5 (19) | 7 (27) | 0.74 |
| High (>10%) | 9 (35) | 9 (35) | 0.77 |
| Low (<5%) | 14 (54) | 13 (50) | 1.00 |
| Moderate (5%–10%) | 5 (19) | 8 (31) | 0.52 |
| High (>10%) | 7 (27) | 5 (19) | 0.74 |
| Low (<5%) | 16 (62) | 12 (46) | 0.26 |
| Moderate (5%–10%) | 3 (12) | 10 (39) | 0.06 |
| High (>10%) | 7 (27) | 4 (15) | 0.49 |
Notes:
According to the European SCORE Risk Charts for Belgium;
Fisher’s exact test was used for subgroups of <10 members.